TowArd demoCRatization Of ev-BAsed Therapiesbroad
ACROBAT · Horizon Europe grant · 2022-05-01–2024-04-30
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2021-ACCELERATORCHALLENGES-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2021-ACCELERATORCHALLENGES-01-01. CORDIS record →
Objective
EVerZom has developed a patented, fast, cost-effective, large-scale standardized extracellular vesicles (EV) production process to address the manufacturing issues that hamper EV translation towards clinic. EVerZom has performed a successful platform scale-up to 6L, meeting quantities needed for phase I trials, placing it at least 2 years ahead of known competitors.With numerous European biotechs poised to enter clinical phase, it’s timely to provide industrial players with EV large-scale capabilities. Hence, EVerZom intends to achieve key milestones during the next 2 years including the validation of platform GMP compliance at clinical phase I scale, the scale-up toward late-stage and commercial batch production as well as platform expansion usefulness towards different cell lines. The ACROBAT project will enable us to be aligned with industrial players roadmap, generate early revenues, and achieve our ambition to be a European pioneer and leader in the EV manufacturing market.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| EVERZOM | FR | coordinator | €1,700,000 | Yes |
Get the EU Defence Funding Calendar — free
The full calendar of open EU defence and dual-use funding calls, sorted by deadline, updated nightly. Delivered with DFM Analysis, our weekly briefing on who is funding what in European defence.
Or browse all open defence & dual-use calls on the funding calendar →
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; the paid Annual Professional subscription is handled on DFM Analysis.